AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
263.76B
Market cap263.76B
Price-Earnings ratio
24.33
Price-Earnings ratio24.33
Dividend yield
1.68%
Dividend yield1.68%
Average volume
2.96M
Average volume2.96M
High today
$169.24
High today$169.24
Low today
$166.26
Low today$166.26
Open price
$166.80
Open price$166.80
Volume
4.08M
Volume4.08M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$153.41
52 Week low$153.41

Stock Snapshot

The current AstraZeneca(AZN) stock price is $166.41, with a market capitalization of 263.76B. The stock trades at a price-to-earnings (P/E) ratio of 24.33 and offers a dividend yield of 1.68%.

As of 2026-10-20, AstraZeneca(AZN) stock has fluctuated between $166.26 and $169.24. The current price stands at $166.41, placing the stock +0.1% above today's low and -1.7% off the high.

The AstraZeneca(AZN)'s current trading volume is 4.08M, compared to an average daily volume of 2.96M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $153.41.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $153.41.

AZN News

Benzinga 5h
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

AstraZeneca Plc (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) on Tuesday shared full results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in adolescents...

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
TipRanks 5h
AstraZeneca Advances Kidney Failure Strategy With New Hemodialysis Drug Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has completed a Phase I trial titled “A Phase I, Single-Centre, Rando...

TipRanks 6h
AstraZeneca Completes Real‑World Asthma Biologic Study in China

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca is tracking how advanced asthma drugs are used in routine care in China, a...

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
0%
Sell
9.1%

More AZN News

Investing.com 9h
AstraZeneca’s tezepelumab shows positive results for esophagitis - Investing.com

...

AstraZeneca’s tezepelumab shows positive results for esophagitis - Investing.com
TipRanks 9h
AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire

Full results from the “positive” Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire demonstrated statistically significant and cli...

Benzinga 13h
Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research

Oracle Corp. (NYSE:ORCL) announced Tuesday a nonbinding agreement with AstraZeneca Plc (NYSE:AZN) to explore using artificial intelligence and real-world data t...

Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
TipRanks 13h
Oracle announces pact with AstraZeneca to advance AI-enabled healthcare

Oracle (ORCL) announced an agreement with AstraZeneca (AZN) to explore how AI and real-world data can help clinicians identify eligible patients for clinical tr...

The Wall Street Journal 16h
AstraZeneca Partners With Oracle to Refine Clinical Research With AI

The first program under the collaboration will focus on hypertension care and clinical research in Abu Dhabi. Paul Ellis / Agence France-Presse / Getty Images...

AstraZeneca Partners With Oracle to Refine Clinical Research With AI
TipRanks 16h
Innate Pharma to Host Q3 2026 Business Update Call

An update from Innate Pharma SA ( (FR:IPH) ) is now available. Innate Pharma SA, a Marseille-based clinical-stage biotech specializing in cancer immunotherapie...

TipRanks 4d
AstraZeneca’s TREVI-OC-03 Trial Signals Fresh Momentum in Ovarian Cancer Maintenance

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is advancing a late-stage study in ovarian and related canc...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.